Personalis
Myriad Genetics, Personalis Cross-License MRD Technology
The companies inked an agreement to co-license their minimal residual disease technology in an effort to broaden testing access and boost adoption.
As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium
MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.